GE HealthCare Technologies Inc. (GEHC) 2022 Q4 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Good day, ladies and gentlemen, and welcome to the GE HealthCare Fourth Quarter 2022 Earnings Conference Call. My name is Michelle, and I'll be your conference coordinator today. As a reminder, this conference is being recorded. I would now like to turn the program over to your host for today's conference, Carolynne Borders, Chief Investor Relations Officer. Please proceed.

    各位女士、各位先生,大家好,歡迎參加 GE HealthCare 2022 年第四季財報電話會議。我是 Michelle,今天將擔任會議協調人。提醒各位,本次會議將被錄音。現在我想把會議交給今天的主持人——投資人關係長 Carolynne Borders。請開始。

  • Carolynne Borders - GE HealthCare Intl

    Carolynne Borders - GE HealthCare Intl

  • Thanks, Michelle. Welcome to GE HealthCare's fourth quarter and full year 2022 earnings call. I'm joined by our President and CEO, Peter Arduini, and Vice President and CFO, Helmut Zodl. Our conference call remarks will include both GAAP and non-GAAP financial results. Reconciliations between GAAP and non-GAAP measures can be found in today's press release, and in the presentation slides available on our website.

    謝謝你,Michelle。歡迎各位參加 GE HealthCare 2022 年第四季及全年財報電話會議。我與我們的總裁暨執行長 Peter Arduini,以及副總裁暨財務長 Helmut Zodl 一同出席。我們在電話會議中的發言將同時包含 GAAP 與非 GAAP 財務結果。GAAP 與非 GAAP 指標之間的調節表可見於今日新聞稿,以及我們網站上提供的簡報投影片。

  • During this call, we'll make forward-looking statements about our performance. These statements are based on how we see things today. As described in our SEC filings, actual results may differ materially due to risks and uncertainties. And with that, I'll hand the call over to Peter.

    在本次電話會議中,我們將就公司表現發表前瞻性陳述。這些陳述係基於我們目前的觀點。如同我們向 SEC 提交的文件所述,實際結果可能因風險與不確定性而出現重大差異。接下來我把電話交給 Peter。

  • Peter Arduini - GE HealthCare Intl

    Peter Arduini - GE HealthCare Intl

  • Thank you, Carolynne. And good morning, everyone. Welcome to our first earnings call as an independent publicly traded company. I'm incredibly proud of the work our team has done to complete the spin-off of GE Healthcare. The energy across the company is palpable and there's tremendous excitement and focus around our purpose to create a world where healthcare has no limits. I want to thank all of our team for their commitment to the customers and patients we serve as we chart our own path forward and execute on our precision care strategy.

    謝謝你,Carolynne。各位早安,歡迎大家參加我們作為一家獨立上市公司後的首次財報電話會議。我對團隊完成 GE Healthcare 分拆上市所做的工作感到無比自豪。公司上下充滿活力,大家對我們的使命——打造一個醫療保健無界限的世界——抱持極大的興奮與專注。我也要感謝所有團隊成員,在我們規劃自身前進道路並執行精準照護策略的同時,持續致力於服務我們的客戶與病患。

  • Let's start with our fourth quarter 2022 performance. We delivered strong organic revenue growth of 13% year-over-year, reflecting an acceleration from prior quarters in 2022. These results were driven by continued robust demand, backlog fulfillment and improved pricing. In addition, supply chain pressures that we experienced earlier in the year eased, continuing the trend that we experienced in the third quarter.

    先從 2022 年第四季表現談起。我們實現了強勁的有機營收年增 13%,較 2022 年前幾季加速成長。這些成果主要來自持續強勁的需求、積壓訂單的交付,以及定價改善。此外,我們在年初所經歷的供應鏈壓力已趨緩,延續第三季的改善趨勢。

  • Adjusted EBIT margin was 17.1%. Volume and price improved in the fourth quarter, but this was offset by inflation, mix, planned R&D investments and some foreign exchange headwinds. We saw sequential margin improvement as volume and price grew and logistics costs eased with the disciplined optimization actions, we've taken across the business. This result is equivalent to 16.1% on a stand-alone basis.

    調整後 EBIT 利潤率為 17.1%。第四季的銷量與價格有所改善,但被通膨、產品組合、既定的研發投資以及部分外匯逆風所抵銷。隨著銷量與價格成長,加上我們在全公司推動的嚴謹優化措施使物流成本下降,我們看到利潤率呈現季比改善。若以獨立公司口徑計算,該結果相當於 16.1%。

  • Adjusted EPS was $1.31, impacted by incremental interest from debt issuance, partially offset by volume and price. In order to facilitate comparability on a go-forward basis, we've also provided a stand-alone adjusted EPS result of $1.06. Free cash flow was $987 million in the fourth quarter, as we start to see supply chain issues ease, and we improve collections year-over-year.

    調整後 EPS 為 1.31 美元,受到發債帶來的新增利息影響,但部分被銷量與價格所抵銷。為了便於未來期間的可比性,我們也提供了獨立公司口徑的調整後 EPS,為 1.06 美元。第四季自由現金流為 9.87 億美元,因供應鏈問題開始緩解,且我們的收款表現較去年同期改善。

  • Total company book-to-bill, which is a calculation of orders to revenues growth, was 1.07x, led by strong orders growth in imaging and ultrasound. For the full year, organic revenues grew 7% year-over-year at the higher end of our mid-single-digit growth target. And while China was impacted by COVID for most of the year, we saw increased momentum coming out of the fourth quarter, and we expect that to continue.

    全公司訂單出貨比(book-to-bill,為訂單相對於營收成長的計算)為 1.07 倍,主要由影像與超音波的強勁訂單成長帶動。全年來看,有機營收年增 7%,位於我們中個位數成長目標區間的高端。雖然中國在大部分年度受到 COVID 影響,但我們在第四季末看到動能回升,並預期將延續。

  • Globally, we have a healthy backlog heading into '23, as customers continue to invest in imaging, ultrasound as well as PCS. 2022 adjusted EBIT margin was 15.6%, impacted by inflationary pressures and planned R&D investments. This is equivalent to the 14.5% on a stand-alone basis.

    全球而言,我們在進入 2023 年時擁有健康的積壓訂單,客戶持續投資於影像、超音波以及 PCS。2022 年調整後 EBIT 利潤率為 15.6%,受到通膨壓力與既定研發投資影響。若以獨立公司口徑計算,該結果相當於 14.5%。

  • Looking ahead, we have several levers to expand margins through strategic pricing, enhancing volume and mix and increasing variable cost productivity as discussed at our Investor Day. Adjusted EPS for the full year was $4.63, and our stand-alone adjusted EPS result was $3.38. Free cash flow was $1.8 billion in 2022, and Helmut will discuss guidance in greater detail here later in the call.

    展望未來,正如我們在投資人日所討論的,我們有多項槓桿可透過策略性定價、提升銷量與產品組合,以及提高變動成本生產力來擴大利潤率。全年調整後 EPS 為 4.63 美元,而獨立公司口徑的調整後 EPS 為 3.38 美元。2022 年自由現金流為 18 億美元;Helmut 稍後將在本次電話會議中更詳細說明財測指引。

  • Overall, we're pleased with the strong performance we delivered in 2022. We're encouraged by the easing supply chain pressures and the resilient end market demand we're seeing across our portfolio, and we remain confident in our ability to drive sustainable value creation in 2023. I'd also like to highlight an important announcement we recently made with the appointment of Dr. Taha KassHout as our Chief Technology Officer.

    整體而言,我們對 2022 年所交出的強勁表現感到滿意。我們也受到供應鏈壓力緩解以及在整體產品組合中所見到的終端市場需求韌性所鼓舞,並對 2023 年持續推動可持續的價值創造充滿信心。我也想強調我們近期的一項重要宣布:任命 Taha KassHout 醫師擔任我們的技術長(CTO)。

  • Taha is leading our science and technology organization as well as our efforts to drive growth through clinical research and the advancement of our digital and machine learning capabilities, specifically our Edison Digital Health Platform. He joins us with deep clinical, digital and machine learning experience. Taha was most recently Vice President of Machine Learning and Chief Medical Officer at Amazon. Taha also served as the FDA's first informatics leader and he's joining the team at a perfect time as we accelerate investments in digital products and software.

    Taha 將領導我們的科學與技術組織,並推動透過臨床研究以及提升數位與機器學習能力來帶動成長,特別是我們的 Edison 數位健康平台。他加入我們時帶來深厚的臨床、數位與機器學習經驗。Taha 最近的職務是 Amazon 的機器學習副總裁暨首席醫療官。他也曾擔任 FDA 的首位資訊學領導者。隨著我們加速對數位產品與軟體的投資,他在此時加入正逢其時。

  • As we invest in our business, we're continuing to make progress on enhancing our operating model to better serve customers to a simplified, more decentralized model. And we're reducing bureaucracy and the organization optimizing our geographic footprint and implement ending platforming initiatives across key product lines.

    在我們投資業務的同時,也持續推進營運模式的強化,以更好地服務客戶,朝向更精簡、更加去中心化的模式轉型。我們也在降低官僚作業並進行組織優化、調整我們的地理布局,並在關鍵產品線推動平台化(platforming)計畫。

  • And with that, let me hand the call over to Helmut to walk through our financials and business segment performance. Helmut?

    接下來,我把電話交給 Helmut,請他帶大家檢視我們的財務與各事業部門表現。Helmut?

  • Helmut Zodl - GE HealthCare Intl

    Helmut Zodl - GE HealthCare Intl

  • Thanks, Pete. Let's take a closer look at our financial performance in the fourth quarter. Revenues of $4.9 billion increased 8% year-over-year, and were up 13% on an organic basis. Reported product revenues increased 13% versus the prior year, led by Imaging, Patient Care Solutions and Ultrasound.

    謝謝,Pete。讓我們更仔細看看第四季的財務表現。營收 49 億美元,年增 8%,以有機基礎計算則成長 13%。公告的產品營收較去年同期成長 13%,主要由影像、病患照護解決方案(Patient Care Solutions)與超音波帶動。

  • Reported Services revenues declined 2%, mainly due to the unfavorable impact of foreign exchange, partly offset by growth in our products, services business. We are pleased with product growth in the quarter that will lead to additional services revenue.

    公告的服務營收下滑 2%,主要因外匯的不利影響,部分被我們產品服務業務的成長所抵銷。我們對本季產品成長感到滿意,這將帶來更多後續的服務營收。

  • Now I'd like to take a -- I'd like to talk about the actions we are taking to increase margins through improving delivery, price and cost. As always, delivering for our customers is our number one priority.

    接下來我想談談我們為了透過改善交付、價格與成本來提升利潤率所採取的行動。一如既往,為客戶交付成果是我們的首要優先事項。

  • We've improved our access to key components, measured by the number of red flag parts that indicate constraints and made good progress in requalifying, redesigning and tool sourcing parts. In fact, we've requalified 7,700 parts since COVID began, and we are now seeing the lowest level of red flag parts, since the first quarter of 2021. We've also applied lean principles to improve our supply chain.

    我們改善了取得關鍵零組件的能力,並以「紅旗零件」數量(代表供應受限的零件)作為衡量指標;同時在零件再認證、重新設計與模具/供應來源開發方面取得良好進展。事實上,自 COVID 開始以來,我們已完成 7,700 個零件的再認證;目前紅旗零件水準已降至自 2021 年第一季以來的最低。我們也運用精實(lean)原則來改善供應鏈。

  • A great example of how we apply lean across the organization was our CT's output initiative this past quarter. We align factory output with customer installations to drive better end-to-end planning. This resulted in an improved customer experience and early deliveries in the quarter. We have achieved a positive sales price index for the third consecutive quarters now.

    本季我們在組織內推動精實的一個很好的例子,是 CT 產出提升計畫。我們將工廠產出與客戶安裝進度對齊,以推動更佳的端到端規劃。這帶來更好的客戶體驗,並使本季出現提前交付。我們已連續第三個季度達成正向的售價指數(sales price index)。

  • And this price accretion occurred across each of our four segments in the fourth quarter. We are pleased with our progress in pricing, and have good visibility on price in our backlog. We are driving variable cost productivity through logistics and material cost reductions. We are also reducing our real estate footprint and optimizing our commercial organization.

    而且這項價格增益在第四季發生於我們四個事業部門的每一個。我們對定價進展感到滿意,並且對積壓訂單中的價格具有良好能見度。我們正透過物流與材料成本降低來提升變動成本生產力。我們也在縮減不動產占用面積並優化商業組織。

  • Turning to Imaging. We saw strong organic revenue growth, up 18% year-over-year, led by molecular imaging, CT, MR and surgery. Our customers remain focused on expansion of capacity and access to care. Looking ahead, we expect imaging demand will remain healthy, supporting top line growth. Following strong revenue growth in the fourth quarter, we expect growth will normalize as we move into the second half of the year.

    接著談影像事業部。其有機營收年增 18%,表現強勁,主要由分子影像、CT、MR 與手術相關業務帶動。我們的客戶仍聚焦於擴充產能與提升照護可近性。展望未來,我們預期影像需求將維持健康,支撐營收成長。在第四季強勁成長之後,隨著進入下半年,我們預期成長將回歸常態。

  • Segment EBIT margin declined 120 basis points year-over-year. We realized improving volume and price, but this was offset by headwinds from inflation, mix and planned investments. Our double-digit investment in imaging R&D this quarter reflects our commitment to innovation and commercial growth. During the quarter, NPIs driving growth included our evolution Apex CT with a scalable detector as well as sNCT with improved imaging and workflow.

    事業部 EBIT 利潤率年減 120 個基點。我們實現了銷量與價格的改善,但被通膨、產品組合與既定投資的逆風所抵銷。本季我們在影像研發的雙位數投資,反映我們對創新與商業成長的承諾。本季帶動成長的 NPI(新產品導入)包括搭載可擴展偵測器的 Revolution Apex CT,以及具備更佳影像與工作流程的 sNCT。

  • Globally we've already seen success using deep learning from improved image quality in MR with (inaudible). We're now very proud to be the first to extend those capabilities to Omni Legend PET CT with precision deep learning available in second select regions.

    在全球範圍內,我們已看到在 MR 上運用深度學習以提升影像品質的成功案例,包含(聽不清)。我們現在也非常自豪成為第一家將這些能力延伸至 Omni Legend PET CT 的公司,並在第二季於部分選定地區提供精準深度學習功能。

  • Sequentially EBIT margin increased 120 basis points driven by improved volume and price. We expect margin expansion in 2023 to be driven by NPIs, commercial execution, supply chain productivity, platforming and digital.

    就季比而言,EBIT 利潤率提升 120 個基點,主要由銷量與價格改善所帶動。我們預期 2023 年的利潤率擴張將由 NPI、商業執行、供應鏈生產力、平台化以及數位化所驅動。

  • Overall, we are investing to drive technology leadership and have the opportunity to increase market share with strategic NPIs, digital and AI leadership, and a focus on care pathways. In addition, we're making progress with platforming initiatives that provide a more consistent user experience and drive parts sensitization and cost reduction.

    整體而言,我們正投資以推動技術領先,並有機會透過策略性 NPI、數位與 AI 領導地位,以及對照護路徑(care pathways)的聚焦來提升市占率。此外,我們在平台化計畫上也持續取得進展,這些計畫可提供更一致的使用者體驗,並推動零件標準化與成本降低。

  • Moving to Ultrasound. Customer demand continues to be strong in both hospitals and other care settings. Organic revenues were up 7% year-over-year, driven by price, improvements in sourcing and fulfillment. Our customer-led innovation continues to drive healthy revenue growth with strong performance in radiology and primary care, women's health and cardiovascular, and our handheld business delivered strong growth in the quarter.

    接著談超音波業務。無論在醫院或其他照護場域,客戶需求仍然強勁。有機營收年增 7%,主要由價格、採購與履約改善所帶動。我們以客戶為導向的創新持續推動健康的營收成長,放射科與基層照護、婦女健康與心血管領域表現強勁,而我們的手持式業務在本季也實現強勁成長。

  • We see continuous traction with our differentiated products including our recently launched Voluson Expert 22 premium ultrasound system for women's health and the Vivid E95 ultrasound edition advanced cardiovascular ultrasound. Both innovations are powered by advanced artificial intelligence tools to help improve workflow, efficiency and productivity. Segment EBIT margin contracted 120 basis points year-over-year.

    我們看到差異化產品持續獲得市場動能,包括近期推出的 Voluson Expert 22 婦女健康高階超音波系統,以及 Vivid E95 超音波版本的先進心血管超音波。兩項創新皆由先進的人工智慧工具驅動,以協助改善工作流程、效率與生產力。該分部 EBIT 利潤率年減 120 個基點。

  • In the fourth quarter, price improved. However, we experienced headwinds from inflation and planned investments. In line with our lean philosophy, we are shifting from stocking inventory to make to order. This initiative is streamlining costs and reducing lead times. We are enabling this through redesign of parts, dual sourcing and platforming. This is an initiative that we will be leveraging across the company, providing additional margin opportunity.

    在第四季,價格有所改善。然而,我們受到通膨與計畫性投資的逆風影響。依循我們的精實理念,我們正從備貨庫存轉向按單生產(make to order)。此舉正在精簡成本並縮短交期。我們透過零件重新設計、雙重採購與平台化來推動這項工作。這是一項我們將在全公司加以運用的計畫,帶來額外的利潤率提升機會。

  • Looking ahead, we are driving sustainable growth in Ultrasound through continued NPI innovation, commercial excellence, and localization. The integration of BK Medical is also well on track.

    展望未來,我們將透過持續的 NPI 創新、商業卓越與在地化,推動超音波業務的永續成長。BK Medical 的整合也進展順利。

  • Let's move to Patient Care Solutions. PCS had a solid fourth quarter, following a year of supply chain challenges, which improved as we exited 2022. Organic revenue was up 10% year-over-year, driven by volume and price improvement. Higher volumes were driven by supply delivery and the launch of NPIs. Looking ahead, we expect fulfillment to improve as we ship our backlog. PCS margins increased 410 basis points compared to fourth quarter '21, with improving price and volume as well as lower cost, partially offset by inflation.

    接著談病患照護解決方案(PCS)。在經歷一整年供應鏈挑戰、並於 2022 年底改善之後,PCS 第四季表現穩健。有機營收年增 10%,由出貨量與價格改善所帶動。較高的出貨量主要來自供應交付以及 NPI 的推出。展望未來,隨著我們出貨積壓訂單(backlog),我們預期履約將持續改善。PCS 利潤率較 2021 年第四季提升 410 個基點,受惠於價格與出貨量改善以及成本下降,但部分被通膨抵銷。

  • The cost favorability drove roughly half of the upside and was associated with onetime items. Sequentially, PCS margins increased significantly due to improving volume and price. We remain focused on innovation and commercial growth investments with R&D investment up double digits in the fourth quarter. Key highlights from the quarter include continued momentum with patient monitoring including Portrait Mobile, CARESCAPE Canvas in Europe.

    成本有利因素約貢獻了上行的一半,且與一次性項目相關。就季比而言,PCS 利潤率因出貨量與價格改善而顯著提升。我們仍聚焦於創新與商業成長投資,第四季研發投資呈雙位數成長。本季重點包括病患監測持續保持動能,包含 Portrait Mobile,以及在歐洲的 CARESCAPE Canvas。

  • Moving to Pharmaceutical Diagnostics. Organic revenues were up 2% year-over-year, impacted by fewer procedures in China due to COVID as well as normalization of U.S. customer inventory. Margins were impacted due to inflationary pressures on raw materials and lower volumes.

    接著談藥物診斷。有機營收年增 2%,主要受到中國因 COVID 導致手術量較少,以及美國客戶庫存正常化的影響。利潤率則因原物料通膨壓力與出貨量較低而受到影響。

  • The team is executing on a pricing strategy that is built around the value we deliver for customers and patients. We continue to monitor the COVID situation closely in China and expect elective procedures to pick up when COVID infections decline. In the fourth quarter, we introduced a new GE Healthcare CT motion detector that will provide better product integration and, in any end, and improve patient experience.

    團隊正在執行以我們為客戶與病患所創造價值為核心的定價策略。我們持續密切關注中國的 COVID 情況,並預期當感染下降時,選擇性手術量將回升。第四季,我們推出新的 GE Healthcare CT 動作偵測器,可提供更佳的產品整合,並在最終改善病患體驗。

  • Next, I'll walk through our cash performance for fourth quarter and full year 2022. During the quarter, we generated $987 million of free cash flow, up year-over-year with improvement in supply chain and collections. With our focus on prioritizing patients and customers, our free cash flow declined for the full year 2022.

    接下來我將說明我們 2022 年第四季與全年現金表現。本季我們產生 9.87 億美元自由現金流,隨著供應鏈與收款改善,較去年同期增加。由於我們聚焦優先滿足病患與客戶需求,2022 全年自由現金流有所下降。

  • But as we enter 2023, we are well positioned to deliver on our backlog. This is a robust and consistent cash flow generating business with a disciplined capital allocation strategy. We are committed through a strong investment-grade rating and will employ a disciplined capital allocation framework. This will include paying down debt and evaluating accretive M&A that advances our precision care strategy. Our balance sheet is strong. As expected, post spin, our day one cash balance was $1.8 billion. Day one leverage, excluding pension, was approximately 2.5x in line with our expectation.

    但進入 2023 年,我們已具備良好條件以交付積壓訂單。這是一項能穩健且持續產生現金流的業務,並採取嚴謹的資本配置策略。我們致力於維持強健的投資等級評等,並將採用紀律性的資本配置框架,包括償還債務,以及評估可增厚(accretive)的併購,以推進我們的精準照護策略。我們的資產負債表強健。如預期,分拆後我們第一天的現金餘額為 18 億美元。第一天槓桿(不含退休金)約為 2.5 倍,符合我們的預期。

  • Let me now move to our 2023 financial outlook. For the full year 2023, we are reaffirming our guidance that was introduced on January 10, calling for year-over-year organic revenue growth in the range of 5% to 7%. We expect stronger organic revenue growth in the first half of the year with more normalized growth in the second half.

    接著談 2023 年財務展望。針對 2023 全年,我們重申 1 月 10 日提出的指引:有機營收年增介於 5% 至 7%。我們預期上半年有機營收成長較強,下半年成長將更趨於常態化。

  • We continue to expect full year adjusted EBIT margin to be in the range of 15% to 15.5%, reflecting an expansion of 50 to 100 basis points over the 2022 stand-alone adjusted EBIT margin of 14.5%. This includes the impact of approximately $200 million of stand-alone costs. Margin expansion in 2023 will be back-half weighted, as transformation initiatives take hold. We expect 2023 adjusted EPS in the range of $3.60 to $3.75, reflecting a growth of 7% to 11%. This compares to 2022 standalone adjusted EPS of $3.38 and includes the impact of the stand-alone costs. We're assuming a tax and adjusted tax rate of 23% to 25%.

    我們仍預期全年調整後 EBIT 利潤率介於 15% 至 15.5%,相較 2022 年獨立口徑調整後 EBIT 利潤率 14.5% 擴張 50 至 100 個基點。此預期包含約 2 億美元的獨立營運成本影響。2023 年的利潤率擴張將偏向下半年,因轉型計畫逐步發揮效益。我們預期 2023 年調整後 EPS 介於 3.60 至 3.75 美元,代表成長 7% 至 11%。相較之下,2022 年獨立口徑調整後 EPS 為 3.38 美元,且已包含獨立營運成本的影響。我們假設稅率與調整後稅率為 23% 至 25%。

  • Free cash flow conversion is expected to be 85% or more for the full year. Our cash flow outlook assumes that the legislation requiring R&D capitalization for tax purposes is repealed or deferred beyond 2023. The free cash flow impact of this legislation is approximately 10 points of free cash flow conversion for the year.

    全年自由現金流轉換率預期為 85% 或以上。我們的現金流展望假設:要求就稅務目的將研發支出資本化的相關立法將被廢止,或延後至 2023 年之後。該立法對全年自由現金流的影響約為自由現金流轉換率 10 個百分點。

  • Second half free cash flow will be substantially higher than the first half of the year, in line with typical cash seasonality due to increased inventory as well as interest and compensation and benefits payments in the first half. Now let me hand back to Pete.

    下半年自由現金流將顯著高於上半年,符合典型的現金季節性,原因包括上半年庫存增加,以及利息、薪酬與福利支付。現在我把時間交回給 Pete。

  • Peter Arduini - GE HealthCare Intl

    Peter Arduini - GE HealthCare Intl

  • Thanks, Helmut. Before we go to questions, I'd like to reiterate, how we're executing against our long-term growth strategy. Our teams are well positioned to deliver on our 2023 commitment. We're investing in organic growth as demonstrated by the introduction of over 40 new products at the RSNA event in November.

    謝謝你,Helmut。在進入提問之前,我想再次強調我們如何落實長期成長策略。我們的團隊已做好準備,能夠達成 2023 年的承諾。我們持續投資於有機成長,正如我們在 11 月 RSNA 活動上推出超過 40 項新產品所展現的。

  • And with workflow solutions enhanced by AI to help healthcare professionals and Health Systems overcome the top operational challenges they face today, while also improving outcomes for patients. We're deepening customer engagement across care pathways, including oncology and cardiology. And we've announced some exciting new products, collaborations and investments that are changing the way healthcare is delivered.

    同時,透過 AI 強化的工作流程解決方案,協助醫療專業人員與醫療體系克服當前面臨的主要營運挑戰,並改善病患的治療結果。我們也在各照護路徑深化客戶互動,包括腫瘤與心臟科。我們並宣布了一些令人振奮的新產品、合作與投資,正在改變醫療服務的提供方式。

  • On the M&A front, we recently announced the agreement to acquire IMACTIS, an innovator and CT interventional guidance. This acquisition, although small, is our first as an independent company and is a great example of the type of transactions that we plan to pursue. They add innovative technology in fast-growing areas that enhances the breadth of capabilities we can deliver for customers.

    在併購方面,我們近期宣布已達成協議收購 IMACTIS——一家在 CT 介入導引領域的創新者。這項收購雖然規模不大,但作為獨立公司後的第一筆收購,是我們計畫追求之交易類型的絕佳例子。他們在快速成長領域帶來創新技術,擴大我們可為客戶提供的能力範疇。

  • In Imaging, we're very proud to announce SIGNA Experience, an MR platform that was -- comes with an integrated set of solutions, including workflow capabilities, an intuitive user interface and deep learning AI applications such as Air Recon DL, which has already reduced scan times for approximately 5.5 million patients globally and is increasing efficiency for clinicians.

    在影像業務方面,我們非常自豪地宣布 SIGNA Experience,這是一個 MR 平台——其配備一整套整合式解決方案,包括工作流程能力、直覺式使用者介面,以及深度學習 AI 應用(例如 Air Recon DL)。該技術已在全球為約 550 萬名病患縮短掃描時間,並提升臨床人員效率。

  • Globally, demand for minimally invasive surgical procedures continues to grow. In the U.S., for example, ambulatory surgical centers are performing more than half of all outpatient procedures. And to serve patients, our customers need efficient imaging capabilities. As a leader in surgery imaging, which is a high-growth and high-margin business for us, we see increasing opportunities for our OEC 3D C-arms to provide precise 2D and 3D images interoperably for many of the clinical applications being done in ASCs, including spine, orthopedics and pulmonary work.

    在全球範圍內,微創手術需求持續成長。以美國為例,門診手術中心(ASC)執行的門診手術已超過全部的一半。為了服務病患,我們的客戶需要高效率的影像能力。作為手術影像領域的領導者(這對我們而言是高成長且高毛利的業務),我們看到 OEC 3D C 臂機在 ASC 進行的多種臨床應用中,提供可互通的精準 2D 與 3D 影像的機會正在增加,包括脊椎、骨科與肺部相關作業。

  • During the fourth quarter, we also announced an $80 million investment in one of our facilities in Norway to increase capacity for our contrast active pharmaceutical ingredient. In our PCS business, we're excited about our Portrait Mobile patient monitoring solution currently available in Europe. This technology allows us to expand care into sub-acute therapy areas, giving providers the ability to monitor patients that aren't always monitored as thoroughly as they should be.

    在第四季,我們也宣布對挪威的一處設施投資 8,000 萬美元,以提升我們顯影劑活性藥物成分(API)的產能。在 PCS 業務方面,我們對目前在歐洲提供的 Portrait Mobile 病患監測解決方案感到振奮。這項技術讓我們能將照護延伸至亞急性治療領域,使醫療提供者能監測那些未必總是被充分監測的病患。

  • In Ultrasound, we're excited about the customer demand for our VIVID Cardiac ultrasound portfolio, which again is equipped with AI features that help improve consistency of assessing the heart muscle's function and significantly reduce the time it takes to acquire those imaging measurements.

    在超音波方面,我們對客戶對 VIVID 心臟超音波產品組合的需求感到振奮;該產品同樣配備 AI 功能,可協助提升評估心肌功能的一致性,並大幅縮短取得這些影像量測所需的時間。

  • And in Digital, we continue to make progress with the development of our Edison Digital Health Platform to help solve customer challenges. We have several pilots underway at hospital systems in the U.S. and Europe, and we expect that cloud-based or on-prem Edison Digital Health Platform will be a vendor-agnostic platform, aggregating data from multiple sources and enabling integrated care pathway management.

    在數位業務方面,我們持續推進 Edison 數位健康平台的開發,以協助解決客戶挑戰。我們已在美國與歐洲的醫院體系展開多項試點,並預期雲端或地端部署的 Edison 數位健康平台將成為供應商中立的平台,彙整多來源資料並支援整合式照護路徑管理。

  • Our goal is that customers will benefit from a wide range of AI applications developed by us and third parties to make better connected decisions, operate more efficiently or better detect trends and populations. These are just a few of the examples of products and partnerships we've invested in to advance our capabilities in precision care. And so, with that, we'd like to open up the call for questions.

    我們的目標是讓客戶能受益於由我們與第三方開發的廣泛 AI 應用,以做出更互聯的決策、提升營運效率,或更好地偵測趨勢與族群。以上只是我們為推進精準照護能力而投資的產品與合作夥伴關係中的幾個例子。那麼,接下來我們開放提問。

  • Carolynne Borders - GE HealthCare Intl

    Carolynne Borders - GE HealthCare Intl

  • Thank you, Peter. I'd like to ask participants to please limit yourself one question and one follow up, so that we can take as many questions as possible during the one hour that we have allotted for the call. Michelle [ph], can you please open the line?

    謝謝你,Peter。我想請各位與會者每人請限制一個問題以及一個追問,這樣我們才能在這通話預留的一小時內盡可能回答更多問題。Michelle [ph],可以請你開線嗎?

  • Operator

    Operator

  • (Operator Instructions) One moment for your questions. Our first question comes from Drew Ranieri with Morgan Stanley. Your line is open.

    (接線員指示)請稍候,我們將開始提問。我們的第一個問題來自 Morgan Stanley 的 Drew Ranieri。您的線路已開通。

  • Drew Ranieri - Morgan Stanley

    Drew Ranieri - Morgan Stanley

  • Hi everyone, thanks for taking the questions.

    大家好,謝謝讓我提問。

  • Peter Arduini - GE HealthCare Intl

    Peter Arduini - GE HealthCare Intl

  • Good morning, Drew.

    早安,Drew。

  • Drew Ranieri - Morgan Stanley

    Drew Ranieri - Morgan Stanley

  • Good morning and congratulations to you and the GE HealthCare team on the spin-off, and Pete, welcome back to more earnings calls. Just maybe first to start on the macro environment. I think there's still some concerns that there will be a capital spending slowdown at some stage.

    早安,也恭喜你們以及 GE HealthCare 團隊成功分拆上市;Pete,也歡迎你回來參加更多的財報電話會議。首先我想從總體環境談起。我認為市場仍然擔心在某個階段資本支出會放緩。

  • Your results, I mean, you're pointing to ongoing demand across your portfolio. But maybe just help us kind of square, what you're seeing from the demand side globally? Maybe what product categories are getting probably the most interest? And do you think there's been any risk of pull forward of capital sales just over the past year or anything? And I have a follow-up. Thanks.

    你們的業績顯示整個產品組合的需求仍在延續。不過能否請你們協助我們釐清一下:你們在全球需求端看到的情況是什麼?哪些產品類別可能最受關注?另外,你們是否認為過去一年資本設備銷售有任何提前拉貨的風險或跡象?我還有一個追問,謝謝。

  • Peter Arduini - GE HealthCare Intl

    Peter Arduini - GE HealthCare Intl

  • Thanks, Drew, for the question. I would just say if I go around the world, start maybe in Europe, there's still robust demand at this point. I think as we've talked about in the past with different audiences that from different sick funds and tenders, to really drive incremental imaging capabilities post COVID.

    謝謝你,Drew,這個問題。我會說,如果我環顧全球,先從歐洲開始,目前需求仍然強勁。我想我們過去也跟不同的聽眾談過,從各種醫療保險基金(sick funds)與招標案來看,確實在 COVID 之後推動了增量的影像能力建置。

  • And so, we see that continuing here into the future. China has obviously been a topic in the news. And although COVID was challenging in Q4, there was quite a bit of investment that we saw going into imaging in particular and in ultrasound. And we believe as the market there works through some of the challenges with COVID in Q1, but there's just a lot of pent-up demand. If you think about '22 and even '21 with some of the lockdowns, there's a lot of people that have a lot of procedures to be taken care of.

    因此,我們看到這樣的趨勢在未來仍會延續。中國顯然一直是新聞焦點。雖然第四季 COVID 帶來挑戰,但我們看到相當多的投資流向影像領域,尤其是影像與超音波。我們相信,當當地市場在第一季逐步消化 COVID 的一些挑戰後,仍有大量被壓抑的需求。若回想 2022 年甚至 2021 年的一些封控,很多人有許多醫療處置需要完成。

  • And in the United States, we were pleased to see with different customers that have reported as well as customers that myself, Helmut and the team have been talking to regularly, are seeing improving conditions. It doesn't mean that they're back to, say, '19 levels, but it means that we're seeing improvements in labor costs. The demand or backlog, meaning the need for imaging procedures, both in our interventional, diagnostic and ultrasound modalities, is still at a record high.

    在美國方面,我們很高興看到,從不同客戶的公開揭露,以及我本人、Helmut 與團隊定期交流的客戶回饋來看,營運狀況正在改善。這不代表已回到例如 2019 年的水準,但代表我們看到人力成本正在改善。需求或積壓訂單(也就是影像檢查程序的需求),無論是在介入、診斷或超音波等模態,仍處於歷史高位。

  • And so, we look, as we start the year, the demand is running strong. I think part of the piece that we all keep an eye on is CapEx prioritization in the United States, I think all indications are that people are being prudent and prioritizing, for sure. But many of the technologies that we offer tend to be prioritized to the higher end of the list and what customers tell us is, in many cases, that added productivity to get patients diagnosed faster, sooner, get them healthier and out of the system is one of the key attributes that we bring.

    因此,當我們在年初觀察時,需求仍然強勁。我認為我們都會持續關注的一點,是美國的資本支出(CapEx)優先順序。所有跡象顯示大家確實更審慎並進行優先排序。不過,我們提供的許多技術往往會被排在較高的優先順序;而客戶告訴我們,在很多情況下,我們帶來的關鍵價值之一,是提升生產力,讓病患更快、更早完成診斷,恢復健康並更快離開醫療體系。

  • So, we're cautiously optimistic. But I'd say, with our large backlog that we have starting the year, we feel good about the horizon that we see here over the next couple of quarters.

    所以我們保持審慎樂觀。但我會說,以我們在年初所擁有的大量積壓訂單來看,我們對未來幾季的能見度感到不錯。

  • Drew Ranieri - Morgan Stanley

    Drew Ranieri - Morgan Stanley

  • Got it. Thank you. Maybe one other question just on the margin expansion, maybe more for (inaudible). But can you maybe help us just bridge the 50 to 100 basis points of improvement for the year? Maybe just talk about is this all really gross margin driven or on the leverage side, but just trying to get a better sense there and maybe how your 5% to 7% organic growth guidance really will drive that margin expansion? And if there's any particular segments that are really going to be the primary beneficiaries? Thank you.

    了解,謝謝。另一個問題是關於利潤率擴張,可能更適合(聽不清)。你們能否協助我們拆解一下今年 50 到 100 個基點的改善來源?這主要是毛利率帶動,還是費用槓桿帶動?我想更清楚了解。另外,你們給的 5% 到 7% 有機成長指引,將如何推動利潤率擴張?是否有特定事業部門會是主要受益者?謝謝。

  • Helmut Zodl - GE HealthCare Intl

    Helmut Zodl - GE HealthCare Intl

  • Yes, thank you, Drew. I think, so when we look at the overall margin expansion in the 50 to 100 basis points, there is a number of drivers in there. So clearly, volume is a driver, VCP, so we have a cost productivity, improvement in material cost improvement in logistics costs and also price is a key driver. So those are really, I would say, those key elements that are driving the levels positive improvement on the margin side.

    是的,謝謝你,Drew。我想,當我們看整體 50 到 100 個基點的利潤率擴張時,裡面有多個驅動因素。很明顯,出貨量(volume)是一個驅動因素;VCP(價值創造計畫)也是,也就是成本生產力、材料成本改善、物流成本改善;此外,價格也是關鍵驅動因素。我會說,這些是推動利潤率正向改善的主要要素。

  • If I look at the headwinds and against that, we're still seeing material costs elevated. So especially material cost that is sitting on our balance sheet, in our inventory currently. And we also continue to invest into the business, both for our growth, but also what we are putting innovation investment in R&D into the business.

    若看逆風因素,我們仍看到材料成本維持在高檔,特別是目前仍在我們資產負債表上、也就是現有庫存中的材料成本。此外,我們也持續投資於業務,一方面為了成長,另一方面也把創新投資、研發(R&D)投入到業務中。

  • So, these are really the offsetting elements. So, both of those elements together are really driving our 50 to 100 basis point margin expansion. And we're very focused on what is really in our control, which is price, VCP and obviously volume execution, that's really how we look at this margin expansion for 2023.

    因此,這些就是相互抵銷的因素。兩者合在一起,推動了我們 50 到 100 個基點的利潤率擴張。我們非常聚焦在我們可控的部分,也就是價格、VCP,當然還有出貨量的執行;這就是我們看待 2023 年利潤率擴張的方式。

  • If I give you a little bit more color, Drew, on the four segments, obviously, as you've seen in the fourth quarter, the Imaging segment, very strong with its growth, we expect that growth, as we work through our backlog, continue especially for the first half.

    如果我再多補充一點、Drew,關於四個事業部門:如你在第四季所見,影像(Imaging)部門成長非常強勁;我們預期,隨著我們逐步消化積壓訂單,這樣的成長將延續,尤其是在上半年。

  • So, there's going to be more close on the imaging side, but also all our other three segments, Ultrasound, PCS and PDx, we expect to grow in that range as we have laid out the 5% to 7% as we go forward. So, it's a quite good balance, as we go into the new year.

    因此,影像端會有更多的動能;但我們另外三個部門——超音波(Ultrasound)、PCS 與 PDx——我們也預期會如同我們所提出的 5% 到 7% 區間持續成長。整體而言,進入新的一年時,組合相當均衡。

  • Operator

    Operator

  • Our next question comes from Edward Ridley-Day with Redburn. Your line is open.

    下一個問題來自 Redburn 的 Edward Ridley-Day。您的線路已開通。

  • Peter Arduini - GE HealthCare Intl

    Peter Arduini - GE HealthCare Intl

  • Good morning.

    早安。

  • Edward Ridley-Day - Redburn

    Edward Ridley-Day - Redburn

  • Good morning. Thank you very much and I'd add my congratulations on your successful spin and your results.

    早安。非常感謝,我也要恭喜你們成功分拆以及本次業績表現。

  • First question for me would be actually around your molecular imaging business, it continues to drive growth in the wider imaging business. Could you help us better quantify the benefits you see there, particularly, what percent of your imaging business does this represent roughly. And also in pharmaceutical diagnostics, you have provided the market breakdown between contrast and molecular.

    我的第一個問題其實是關於你們的分子影像(molecular imaging)業務,它持續帶動更廣泛的影像業務成長。你們能否協助我們更量化地了解你們看到的效益,特別是:這大約占你們影像業務的百分之多少?另外,在藥物診斷(pharmaceutical diagnostics)方面,你們已提供市場在顯影劑(contrast)與分子之間的拆分。

  • But what percent of pharmaceutical diagnostics is radiopharmaceuticals, there's a great opportunity, so be great to have any color, you can give on that. And just a quick follow-up on pricing. Could you give us an idea of the price -- rough price increase you hope to push through for this year? Thank you.

    但在藥物診斷中,放射性藥物(radiopharmaceuticals)占比是多少?這是一個很大的機會,因此若你們能提供任何相關說明會很有幫助。最後快速追問一下定價:你們能否讓我們了解一下,今年希望推動的價格上調幅度大概是多少?謝謝。

  • Peter Arduini - GE HealthCare Intl

    Peter Arduini - GE HealthCare Intl

  • Thanks Ed, for the questions. Yes, I'll start maybe a little bit with MI and frame it up, and then maybe Helmut, you can comment a little bit on price.

    謝謝你,Ed,這些問題。是的,我先從 MI 稍微談起並做個框架整理,然後也許 Helmut 你可以補充一下定價。

  • I would start first with saying, yes, I think one of the really interesting things that we're excited about strategically is we're the only company out there that actually makes the fuels for molecular imaging as well as, as the devices that capture to create the images themselves.

    我先說,沒錯,我們在策略上非常興奮的一點是:我們是市場上唯一一家同時製造分子影像的「燃料」(也就是示蹤劑/藥劑)以及用來擷取並生成影像的設備本身的公司。

  • Why that's important is this rise of different technologies out there called theranostics, this combination of a therapy and a diagnostic together, and how you tune the device to the agent whether it would be in the neuroscience area, such as Parkinson's or amyloid beta plaque imaging or other parts of the body, there's a lot of longer-term benefits we think will come that way.

    這之所以重要,是因為目前有一類正在興起的技術稱為「診療一體」(theranostics),也就是把治療與診斷結合在一起;以及你如何讓設備與藥劑相匹配、相調校——不論是在神經科領域,例如帕金森氏症或 β 類澱粉蛋白斑塊(amyloid beta plaque)影像,或是身體其他部位——我們認為長期會帶來許多效益。

  • Our -- in the agent business itself, MI, the agents are about 1/3 of volume, about 2/3 is contrast imaging agents used in the X-ray equipment, but we believe that's going to be a growing area with, again, newer capabilities coming out of the pharma space that we play a critical role in helping do the diagnostics.

    就藥劑業務本身而言,MI 的藥劑約占三分之一的量,約三分之二是用於 X 光設備的對比顯影劑(contrast imaging agents);但我們相信,隨著製藥領域推出更新的能力,而我們在協助完成診斷上扮演關鍵角色,這將會是一個成長領域。

  • On the device side itself, we've got a great platform, a great team. We do some outstanding work here in the United States as well as in Israel on these devices, probably one of the deeper expertise capabilities on different technologies, whether they be BGO or LSO, different types of PET/CT detectors as well as the CDT expertise we have within our MI devices.

    在設備端,我們有很好的平台與團隊。我們在美國以及以色列在這些設備上都做了非常出色的工作;在不同技術上可能具備更深的專業能力——不論是 BGO 或 LSO、不同類型的 PET/CT 偵測器,以及我們在 MI 設備中所具備的 CDT 專業能力。

  • And combined between PET and MI, we think that this is going to be a continuing growth area. It's still, at this point, compared to MR and CT, a more moderate sized business.

    而在 PET 與 MI 的合併來看,我們認為這會是一個持續成長的領域。不過就目前而言,相較於 MR 與 CT,它仍是一個規模較為中等的業務。

  • But again, with the rise of these new technologies, and give you an example, if an agent comes out that needs this type of follow-up, to actually assess either amyloid beta plaque or other capabilities, we believe our MI technologies - the MI technologies out in the industry will really play a key role in helping driving that diagnosis. And then down the road can even play a larger role in the therapy process, either dose or delivery of agent. So, Helmut, you may want to comment a little bit on the pricing question.

    但同樣地,隨著這些新技術的興起,舉例來說,如果有一種藥劑推出後需要這類追蹤檢查,來評估 β 類澱粉蛋白斑塊或其他能力,我們相信我們的 MI 技術——以及產業中的 MI 技術——將在推動該診斷上扮演關鍵角色。再往後,甚至能在治療流程中扮演更大的角色,例如劑量(dose)或藥劑投遞(delivery of agent)。所以,Helmut,你可能想針對定價問題補充一下。

  • Helmut Zodl - GE HealthCare Intl

    Helmut Zodl - GE HealthCare Intl

  • Yes, thanks, Pete. So everyone, on price, we're quite happy with the progress we've been making on price throughout the year. So, we started really tracking in a price on orders in the last year. So, we have both management system that looks at the orders but also looks at how much price we have in sales. And in sales, since the second quarter, we have priced in our sale.

    是的,謝謝,Pete。所以各位,關於價格方面,我們對今年以來在價格上的進展感到相當滿意。我們從去年開始真正追蹤訂單中的定價。因此,我們同時有一套管理系統,既看訂單,也看我們在銷售中實現了多少價格。在銷售端,自第二季以來,我們已在銷售中反映了定價。

  • So in revenue, it started at the low single digit, it improved as it went through the third quarter. And we are now in first [ph] - some of our modality is in the mid-single-digit level what we are seeing on price. So, we really are happy about how performed. And we also have good visibility on price within our backlog. So, we already know what is going to happen and ship here over the next quarters and how much price is in that - in that backlog.

    因此在營收上,一開始是低個位數,到了第三季逐步改善。而我們現在在第一個[聽不清]——我們的一些產品線(modality)在價格上呈現中個位數的水準。對於表現我們確實很滿意。我們也對訂單積壓(backlog)中的價格有很好的能見度。因此,我們已經知道接下來幾季會發生什麼、會出貨什麼,以及那個——那個積壓中包含多少價格因素。

  • Carolynne Borders - GE HealthCare Intl

    Carolynne Borders - GE HealthCare Intl

  • Michelle [ph], we'll take our next question.

    Michelle[聽不清],我們來接下一個問題。

  • Operator

    Operator

  • Thank you. Our next question comes from Vijay Kumar with Evercore. Your line is open.

    謝謝。下一個問題來自 Evercore 的 Vijay Kumar。您的線路已開通。

  • Vijay Kumar - Evercore

    Vijay Kumar - Evercore

  • Hey, guys. Congratulations on a - on a nice spring share and thanks for taking my question.

    嗨,各位。恭喜你們——股價有不錯的表現,也謝謝你們回答我的問題。

  • Peter Arduini - GE HealthCare Intl

    Peter Arduini - GE HealthCare Intl

  • Thank you.

    謝謝。

  • Vijay Kumar - Evercore

    Vijay Kumar - Evercore

  • Maybe my first question's here on the guidance assumptions here. Peter, can you talk about any trends in the cancellation rates or cadence that we need to give our - when you look at the five to seven, what is pricing? How much of that five to seven do you have visibility, given the backlog and the booked-to-bill ratios here?

    我第一個問題是關於指引假設。Peter,你能談談取消率(cancellation rates)或節奏(cadence)是否有任何趨勢,是我們需要納入考量的嗎——當你看 5% 到 7% 的區間時,定價(pricing)占比是多少?考量到目前的訂單積壓以及 book-to-bill 比率,你對這個 5% 到 7% 有多少能見度?

  • Peter Arduini - GE HealthCare Intl

    Peter Arduini - GE HealthCare Intl

  • Yes, Vijay, look, good question. We have some actually quite good visibility at this point. With carrying a little bit of a larger backlog than we normally do, one of the advantages of that is we actually have greater visibility out into the distance about what the deals look like, what the margin is on the deal, the timing thereof.

    是的,Vijay,這是個好問題。我們目前其實有相當不錯的能見度。由於我們目前維持的訂單積壓比平常稍大,其中一個優勢是,我們對更長期的情況有更高的能見度:交易長什麼樣子、交易的毛利是多少、以及其時點。

  • And one of the things our operating teams in each of the segments have done a very nice job, is actually speaking with customers and getting all the install-based products planned out as far as we can go, which is, in many cases, a couple quarters out, which is longer than we have historically done. But we did that purposely just based on some of the questions within the macro environment.

    而我們各事業部的營運團隊做得非常好的一點,是實際與客戶溝通,並把所有以裝機為主(install-based)的產品規劃到我們能規劃的最遠,很多情況下可以看到未來幾個季度,這比我們過去歷史上做得更遠。但我們是刻意這麼做的,主要是基於總體環境中的一些疑問。

  • And so, that gave us more confidence, obviously, here about what customers want and when they want it. And we've got some pretty good visibility into that. Other businesses, such as ultrasound that have more flow capabilities based on prospecting funnels and stuff, we have quite good visibility as well.

    因此,這讓我們對客戶想要什麼、以及他們何時想要,顯然更有信心。我們對此有相當好的能見度。其他業務,例如超音波(ultrasound),因為有更多依賴商機漏斗(prospecting funnels)等帶來的流量能力,我們同樣也有相當好的能見度。

  • So, if we look at - if we look a that backlog, we know what the cost - the input costs are going into that. We have - we know what the prices in the backlog. So again, for those deals it's quite good. We clearly have orders coming into the system that will feed into that backlog. We know what our current pricing is. And we've also either taken some price increases or had some that would cut in.

    所以,如果我們看——如果我們看那個訂單積壓,我們知道投入其中的成本——投入成本是多少。我們也——知道積壓中的價格。因此,再次強調,對於那些交易,我們的能見度相當好。當然也會有新訂單進入系統並補充到積壓中。我們知道目前的定價水準。我們也已經採取了一些漲價,或有一些漲價會在之後生效。

  • And keep in mind, there's a couple different ways to think about price. Looking at your configurations and really optimizing them is something that we started last year, and I think that's of high value.

    另外請記住,思考價格有幾種不同方式。檢視你的配置(configurations)並真正把它最佳化,是我們從去年開始做的,我認為這非常有價值。

  • Our new NPIs, we really focus on getting the right value for the customer and pricing it right the first time, which typically then aligns to making sure that we have the right gross margins associated with it. And then, classic price increases on many of our products. So again, the combination of those gives us a pretty good view into how we see the year at this point. But probably more so, a better lens on the first half.

    對於我們的新產品導入(NPIs),我們非常專注於為客戶取得正確的價值,並在一開始就把價格定對,這通常也會對齊到確保我們有相應的正確毛利率。然後,對我們許多產品進行傳統的漲價。因此,這些因素的組合,讓我們對今年目前的看法有相當好的掌握。不過更重要的是,對上半年我們有更清晰的視角。

  • Vijay Kumar - Evercore

    Vijay Kumar - Evercore

  • Understood. That's helpful. And maybe one follow-up for Helmut. Look at EPS guidance here, assembly [ph] 11, between your organic top line assumptions and margin expansion, I think operating profit should be growing close to double-digits here. Any - what are you assuming for FX? And any below-the-line sensitivity here on interest expense or other items that we need to be aware of?

    了解,這很有幫助。再追問 Helmut 一個問題。看 EPS 指引這裡,assembly[聽不清] 11,在你們有機營收假設與毛利率擴張之間,我認為營業利益應該接近雙位數成長。你們對匯率(FX)假設是什麼?另外在業外(below-the-line)方面,利息費用或其他項目有沒有什麼敏感度是我們需要注意的?

  • Helmut Zodl - GE HealthCare Intl

    Helmut Zodl - GE HealthCare Intl

  • Yes, so Vijay, we have been, obviously, tightening up the range on the APPS guide. So, the $3.60 or $3.75 percent we believe is right in the middle. When you look at the upper and lower end of the revenue end, the margin expansion guide, so we wanted to tighten that range up. And two year or to the assumption question, so there is about 2.5 basis points of negative impact from FX assumed in those numbers, very little below the line. So that's really how you - how you should look at that.

    是的,Vijay,我們顯然已經把 EPS 指引區間收斂了。所以,我們認為 3.60 美元到 3.75 美元是落在中間的合理區間。當你看營收區間的上下緣、以及毛利率擴張指引時,我們希望把那個區間收緊。至於你的假設問題,這些數字中假設匯率(FX)約有 2.5 個基點的負面影響,業外項目影響很小。所以你應該用這樣的方式來看。

  • Peter Arduini - GE HealthCare Intl

    Peter Arduini - GE HealthCare Intl

  • Yes, and I would just say, one of the things is we've got - and we've talked about improving supply chain, but again, improving isn't back to say the good ole days. All of our input costs have some added cost to them, it's why we've put a lot of focus on variable cost per activity.

    是的,我也想補充一點:我們已經——而且我們談過改善供應鏈,但再次強調,改善並不代表回到過去的好日子。我們所有的投入成本都增加了一些額外成本,這也是為什麼我們把重點放在每項活動的變動成本(variable cost per activity)上。

  • We're carrying some inventory from spot buys and things, that was at higher rates. And we're going to see much of that continue into '23. But we have good visibility to it. And I think as we see how the economy plays out and how that plays out relative to inflation, we'll have better insights about what we can do about it. But again, our first half visibility looks quite good at this point in time. And again, we're optimistic that we're going to continue to see improvement throughout the year.

    我們也持有一些來自現貨採購(spot buys)等的庫存,那些是以較高的價格買進的。我們會看到其中很大一部分延續到 2023 年。但我們對此有很好的能見度。我認為,隨著我們觀察經濟走勢,以及它相對於通膨的表現,我們會更清楚能做些什麼。不過再次強調,就目前而言,我們對上半年的能見度相當好。而且我們也樂觀認為,全年會持續看到改善。

  • Vijay Kumar - Evercore

    Vijay Kumar - Evercore

  • That's helpful perspective. Thank you, guys.

    這個觀點很有幫助。謝謝各位。

  • Peter Arduini - GE HealthCare Intl

    Peter Arduini - GE HealthCare Intl

  • Thank you.

    謝謝。

  • Operator

    Operator

  • Thank you. Our next question comes from Larry Biegelsen with Wells Fargo. Your line is open.

    謝謝。下一個問題來自 Wells Fargo 的 Larry Biegelsen。您的線路已開通。

  • Larry Biegelsen - Wells Fargo

    Larry Biegelsen - Wells Fargo

  • Good morning.

    早安。

  • Peter Arduini - GE HealthCare Intl

    Peter Arduini - GE HealthCare Intl

  • Good morning, Larry.

    早安,Larry。

  • Larry Biegelsen - Wells Fargo

    Larry Biegelsen - Wells Fargo

  • Hey, Pete. Hi, Helmut. Thanks for taking the question. One on the top line, one on the margins. Pete, you talked about, clearly, Q4 results were very strong, 18% in imaging. You talked about it - the backlog here. Is there - is there any way to quantify this? Is there - I mean, is this somewhat of a catchup if you will? And what are your expectations for that, for '23? Clearly, you're growing well in excess of historical market growth. And I had one follow-up.

    嗨,Pete。嗨,Helmut。謝謝你們回答問題。我有一個關於營收、一個關於毛利率。Pete,你提到第四季結果非常強勁,影像(imaging)成長 18%。你也談到這裡的訂單積壓。有沒有——有沒有辦法量化一下?我的意思是,這在某種程度上算是補回(catch-up)嗎?那你們對 2023 年的預期是什麼?很明顯你們的成長遠高於歷史市場成長。我還有一個追問。

  • Peter Arduini - GE HealthCare Intl

    Peter Arduini - GE HealthCare Intl

  • Yes, Larry, I think particular to imaging we, obviously, as well as us and pretty much everyone in other industries, with the installed type products had some pent-up demand. And, I mean, that's part of our backlog, right? And we were able to deliver a higher percentage of that. That typically is more in MRs, CT, PET/CT, again, some of the bigger installation-based products. But it's affected the whole portfolio at some level.

    是的,Larry,我想就影像而言,我們當然——以及我們,還有幾乎所有其他產業——在這類裝機型(installed type)產品上都有一些被壓抑的需求(pent-up demand)。而且,我的意思是,那也是我們訂單積壓的一部分,對吧?我們也能交付其中較高比例。這通常更多出現在 MR、CT、PET/CT 等,也就是一些較大型、以安裝為主的產品。但在某個程度上,它影響了整個產品組合。

  • And so, Helmut mentioned the words, we focused on making sure that we leaned in on getting the parts that we needed at the right time. It had a little bit of an impact on our cash flow, but we had the components available to ship, which then resulted in the higher growth. And I think with that we're going to see that into the first half. Now, we would - we would expect that will start moderating and get back to more classical, historic growth rates.

    因此,Helmut 提到的重點是,我們專注於確保在正確的時間取得所需零組件。我們的現金流因此受到一點影響,但我們有足夠的元件可以出貨,進而帶來較高的成長。我認為這種情況會延續到上半年。接著我們——我們預期它會開始趨於溫和,回到較典型、歷史性的成長率。

  • But what's interesting is you speak with customers, again, back on the list of their top capital buys, in many cases, diagnostic imaging equipment. MR ranks up there high. We'd mentioned the OECC arms in our remarks. Anybody that's doing any type of surgical imaging in outpatient center that's the preferred device. So, it's quite strong, but we are definitely running at a higher level. And our RPO or our backlog that we have is quite strong. And again, just to emphasize, we've got good visibility on that into '23 and well into the year.

    但有趣的是,你與客戶交談時,他們的資本支出採購清單上,很多情況下診斷影像設備仍然名列前茅。MR 排名很高。我們在談話中也提到 OECC C-arm。任何在門診中心做各類手術影像的人,這都是首選設備。所以需求相當強勁,但我們確實是在較高水準運行。我們的 RPO 或目前的訂單積壓也相當強勁。再次強調,我們對 2023 年、以及全年進展都有很好的能見度。

  • Larry Biegelsen - Wells Fargo

    Larry Biegelsen - Wells Fargo

  • Thank you. And Helmut, on - well, sales and margin cadence, appreciate the color. Maybe if you could calibrate us a bit more. How much lower do you expect second half organic growth? Is it going to below the 5% to 7%? And then margins, kind of how much - how much lower in the - in the first half do you still expect to be down year-over-year? Thanks for taking my question.

    謝謝。Helmut,關於——嗯,銷售與毛利率的節奏,謝謝你提供的資訊。也許你可以再幫我們校準得更清楚一些:你預期下半年有機成長會低多少?會低於 5% 到 7% 嗎?另外毛利率方面,上半年你仍預期年對年會下降多少?謝謝你回答我的問題。

  • Helmut Zodl - GE HealthCare Intl

    Helmut Zodl - GE HealthCare Intl

  • Yes, Larry, so maybe I'll reiterate how we look at the overall guidance for the full year and the quarterly flow. So on revenue, we expect growth to be stronger in the first half, clearly. And that is driven by the backlog and also how we have lined up really past an inventory in the first half accordingly.

    是的,Larry,那我再重申一下我們如何看待全年整體指引以及季度走勢。就營收而言,我們預期上半年成長會更強,這很明顯。這主要由訂單積壓所驅動,同時也因為我們在上半年相應地安排了——真的把庫存配置到位。

  • But the good news is going to be that I will - we still expect sequential growth in the - in the - into the second half. So typically, our Q3 and Q4 is higher than our Q1 and Q2. But growth rates we expect to be slightly lower than what we are seeing in the first half accordingly. So, that's the side on the revenue.

    但好消息是,我們仍然預期在下半年會出現連續性的成長。因此通常我們的第三季與第四季會高於第一季與第二季。不過,相較於我們在上半年所看到的情況,我們預期成長率會略低一些。所以,以上是營收面的說明。

  • On the margin side, you will see, I think, in a more fixed margin expansion in the second half as we expect some of those productivity initiatives to take a hold, especially around BCP and cost improvement on the gross margin side. And the reason for that is really because we still have, as I think Pete said this earlier, we still have elevated costs that is sitting in our inventory on our balance sheet. And as we flush that in our inventory through we will have in the lower margins in the first half but then we'll improve into the second half.

    在毛利率方面,我認為你會看到下半年出現較為明顯的固定式毛利率擴張,因為我們預期部分生產力提升計畫將開始發揮效果,特別是在 BCP 以及毛利端的成本改善上。其原因主要是因為我們仍然有(如 Pete 先前提到的)偏高的成本,仍然以庫存形式留在資產負債表上。當我們把這些庫存逐步消化後,上半年毛利率會較低,但下半年會改善。

  • And we're already seeing this based on those red flags passed of how much parts we have, how much parts we have to purchase, (inaudible). And so, that's going to be the side on the margins and more of that in the second half. And maybe I'll comment on cash flow also, just to be clear on that also.

    而且我們已經從那些警訊中看到這點,例如我們有多少零件、我們必須採購多少零件,(聽不清)。因此,這將是毛利率面的情況,而且下半年會更明顯。也許我也補充一下現金流,讓這點更清楚。

  • So, a very large piece of the cash flow given our seasonality in our business we expect to happen in the second half, less of cash is going to be generated in the first half because of interest payments, because of some of the supplier payments that began in the first half as well. So, that's really how we - how you should look at the quarterly flow for 2023.

    因此,考量到我們業務的季節性,現金流中非常大的一部分我們預期會發生在下半年;上半年產生的現金會較少,原因包括利息支付,以及部分供應商款項也在上半年開始支付。所以,這就是你應該如何看待 2023 年各季現金流的方式。

  • Operator

    Operator

  • Our next question comes from Veronika Dubajova with Citi. Your line is open.

    下一個問題來自 Citi 的 Veronika Dubajova。您的線路已開通。

  • Veronika Dubajova - Citi

    Veronika Dubajova - Citi

  • Hi, good morning. And thank you guys for taking questions. And congratulations on the successful spend as well.

    嗨,早安。謝謝各位回答問題,也恭喜你們成功完成分拆。

  • Peter Arduini - GE HealthCare Intl

    Peter Arduini - GE HealthCare Intl

  • Thanks, Veronika.

    謝謝你,Veronika。

  • Veronika Dubajova - Citi

    Veronika Dubajova - Citi

  • Maybe you guys can talk a little bit about the competitive environment that you are seeing. And I'm thinking, in particular, in imaging and ultrasound. Curious if you're seeing any changes. We saw one of your peers this morning cancel some historic orders, which they felt were at a lower price.

    也許你們可以談談目前看到的競爭環境。我特別想到影像與超音波領域,想了解你們是否看到任何變化。我們今天早上看到你們的一家同業取消了一些歷史訂單,因為他們認為那些訂單的價格較低。

  • Is that creating opportunities? Or in general, are you seeing opportunities that are driven by the disruption that this one peer of yours has suffered? And maybe specifically, if you can comment on China and how the local strategy is playing out for you guys? Then I have one follow-up after that, but I appreciate this is a long question, so I'll let you answer that first.

    這是否正在創造機會?或者更一般地說,你們是否看到因為這家同業遭遇的干擾而帶來的機會?另外,也請你們特別評論一下中國,以及在中國的在地化策略對你們的推進情況如何?我後面還有一個追問,但我知道這問題很長,所以先讓你們回答這一題。

  • Peter Arduini - GE HealthCare Intl

    Peter Arduini - GE HealthCare Intl

  • Yes, Veronika. I would say, look, from an environment in the marketplace, I would say a little bit just because of some of the dynamics here that there's quite a bit of demand that's actually out in the marketplace when you look at these backlogs of imaging procedures.

    是的,Veronika。我會說,就市場環境而言,因為這裡的一些動態,當你看影像檢查程序的積壓量(backlog)時,市場上其實存在相當多的需求。

  • And so, all the different places I think at some level are having some positive benefits of this market. I mean, again, the prioritization of the CapEx just doesn't apply to GE HealthCare, right? It applies to everybody.

    因此,我認為各家在某種程度上都能從這個市場中獲得一些正面效益。我的意思是,再次強調,資本支出(CapEx)的優先順序調整不只適用於 GE HealthCare,對所有人都一樣。

  • And so, we're expecting that there's a reasonable healthy amount of demand out there. And everyone at some level has had different experiences and challenges with their supply chain. So there is some similarities.

    因此,我們預期外部仍有合理且健康的需求量。而且每家公司在供應鏈方面都在不同程度上有各自的經驗與挑戰,所以也有一些相似之處。

  • At the same time, we think because of the investments that we've made over the past few years, we have some products that are winning share, more so about the capabilities they bring to patients and customers than a situation where maybe one or two of our competitors are in.

    同時,我們認為因為過去幾年所做的投資,我們有一些產品正在贏得市占;這更多是因為它們為病患與客戶帶來的能力,而不是因為我們某一兩個競爭對手所處的情況。

  • And so, I mentioned molecular imaging where we've got leadership positions. What we've done in MR with our image quality as we as productivity, our CT, surgery, what's come out with ultrasound, that's how we're winning the day and in many cases, taking share in different marketplaces. I would say we are really being balanced about what we go after to make sure that we get the right margins and capability around. So that's an important part of our overall strategy.

    因此,我提到分子影像,我們在那裡具備領先地位;我們在 MR 上所做的影像品質與生產力提升、我們的 CT、手術,以及超音波推出的新產品,這些都是我們能在市場上勝出的原因,且在許多情況下在不同市場取得市占。我會說,我們在追求哪些機會上非常平衡,以確保取得正確的毛利率與能力配置。因此,這是我們整體策略的重要部分。

  • I would say to your China question, look, there's always been lots of local competitors. And many of our modalities for 10 to 20 years there's been 5x or 4x the amount of competition within China for China versus the rest of the world.

    至於你問到中國,我想說,中國一直都有很多本地競爭者。在我們許多產品線(modality)上,過去 10 到 20 年,中國市場內的競爭數量大約是全球其他地區的 4 倍到 5 倍。

  • And I think as you know, we've been competing there for many, many years, manufacturing for over 30. So we have a pretty good handle on it. And with some of the stimulus funds that were -- the government put out really at the beginning of Q4, we've been seeing some robust demand for imaging equipment in particular, both ultrasound and the whole spectrum of the imaging portfolio.

    而且我想你也知道,我們在那裡競爭很多年了,製造也超過 30 年,所以我們對此掌握得相當好。隨著政府在第四季初推出的一些刺激資金,我們看到影像設備(特別是超音波以及整個影像產品組合)出現強勁需求。

  • And again, I think we're going to see that continue into beginning of next year. And so, we've been able to be quite successful, we believe, in competing against both multinational as well as local competitors.

    而且,我認為這種趨勢會延續到明年年初。因此,我們相信自己在與跨國以及本地競爭者競爭時,都能取得相當不錯的成果。

  • We see ourselves in many cases as local, as a local player in many of our modalities, again, because of how we actually design and make products in China for China. You have another question?

    在許多產品線上,我們在很多情況下把自己視為在地、作為本地玩家,因為我們確實是在中國為中國設計並製造產品。你還有另一個問題嗎?

  • Veronika Dubajova - Citi

    Veronika Dubajova - Citi

  • Yes, I did, which was China specifically, if you can just remind us what proportion of your portfolio is certified as local now? And when might we hit 100%?

    有的,關於中國,我想請你們提醒一下:目前你們的產品組合中,有多少比例已取得本地化認證?以及什麼時候可能達到 100%?

  • Helmut Zodl - GE HealthCare Intl

    Helmut Zodl - GE HealthCare Intl

  • Yes. So Veronika, we have a very large components of our portfolio is localized. And I would say it's not close to 100%, but not far off 100%. That's how I would answer the question for most of our modalities. And we continue to expand that on an ongoing basis because it's not only the localization of the manufacturing, but it's also the innovation in China.

    好的。Veronika,我們產品組合中有非常大一部分已經本地化。我會說,距離 100% 還不到,但也不算遠。對於我們大多數產品線,我會這樣回答。而且我們也持續在擴大本地化,因為這不只是製造的本地化,也包括在中國的創新。

  • So having specific product that's really made for China, made in China. That's really how we look at it. So innovating for the China market accordingly. So this is quite high percentages. The teams worked very hard.

    也就是擁有真正為中國打造、在中國製造的特定產品。這就是我們看待這件事的方式:針對中國市場進行創新。因此比例相當高,團隊也非常努力。

  • And we have a long -- as Pete said earlier, we have a long history in China. It's an important market for us. Our brand is very well recognized, which we are proud of, and we are continuing to innovate for customers in China.

    而且我們在中國有很長的歷史——如 Pete 先前所說,我們在中國有很長的歷史。這對我們而言是重要市場。我們的品牌辨識度非常高,我們也以此為榮,並持續為中國客戶創新。

  • Peter Arduini - GE HealthCare Intl

    Peter Arduini - GE HealthCare Intl

  • And I would just to put a finer point on it, Veronika, I mean, for what we have said as our operating plan for '23, we have all of that localized and feel quite good about it. As Helmut said, as we bring new products out, one of the big questions is how much are you going to localize versus not, but for what we need to compete we're in a very good position with localized components and that type of recognition that's needed in certain types of tenders or constructs to compete.

    再更精確地說,Veronika,就我們所說的 2023 年營運計畫而言,我們已將其全部本地化,並且對此相當有信心。如 Helmut 所說,當我們推出新產品時,一個重要問題是你要本地化到什麼程度、哪些不本地化;但就我們競爭所需而言,我們在本地化零組件以及在某些標案或架構中所需的認可方面,都處於非常有利的位置。

  • Operator

    Operator

  • Our next question comes from Anthony Petrone with Mizhuo. Your line is open.

    下一個問題來自 Mizhuo 的 Anthony Petrone。您的線路已開通。

  • Peter Arduini - GE HealthCare Intl

    Peter Arduini - GE HealthCare Intl

  • Hi, Anthony.

    嗨,Anthony。

  • Helmut Zodl - GE HealthCare Intl

    Helmut Zodl - GE HealthCare Intl

  • Morning, Anthony.

    早安,Anthony。

  • Anthony Petrone - Mizhuo

    Anthony Petrone - Mizhuo

  • Hi. Hi, Pete. Hi, Helmut. Congratulations on the spin and a great initial quarter out of the gate here. So congratulations to the team.

    嗨。嗨,Pete。嗨,Helmut。恭喜完成分拆,也恭喜剛起步就交出很棒的第一季表現。恭喜團隊。

  • Maybe a little bit on new product introductions, MPIs, and even that is certainly a contributor here. So in the plus 13% overall, I guess what percent of t hat actually came from new products?

    我想問一下新產品導入、MPI(新產品導入指標)等,這顯然也是本季的貢獻因素之一。在整體成長超過 13% 的情況下,我想問其中有多少百分比實際上來自新產品?

  • And then when we think about the backlog, what is embedded in there for new products? What percentage of the backlog is going to flow through with newer systems that are recently introduced, let's say, over the last 12 to 18 months? And I'll have one quick follow up on capital allocation.

    另外,當我們思考積壓訂單(backlog)時,其中有多少是新產品所帶來的?在積壓訂單中,有多少比例會由近期導入的新系統來消化,例如過去 12 到 18 個月內推出的產品?最後我還有一個關於資本配置的簡短追問。

  • Peter Arduini - GE HealthCare Intl

    Peter Arduini - GE HealthCare Intl

  • Yes, Anthony. I'll make some comments, and Helmut, feel free to jump in. I think, again, in this business, having new products that bring solutions that solve some of the challenges for customers, in many cases, productivity, products that help deal with some of the labor challenges or expertise and then solving big issues for patients.

    好的,Anthony。我先做一些評論,Helmut 也歡迎補充。我認為,在這個產業中,推出能提供解決方案、能解決客戶某些挑戰的新產品非常重要;很多時候是生產力相關,或是能協助應對人力短缺或專業人力不足的產品,並且能為病患解決重大問題。

  • We've been quite fortunate with a lot of our launches recently, again, in some of the classic modalities, MRCT, we mentioned about the PET system that has integrated AI on it. All of those have played a key role.

    我們最近許多產品上市表現相當不錯,我們也很幸運;同樣是在一些經典產品線上,例如 MR、CT。我們也提到那套整合 AI 的 PET 系統。這些都扮演了關鍵角色。

  • I think in the fourth quarter, we were in the upper 20s, high 20s or so relative to vitality rate on new products that have been recently launched. My metric typically is if you're above 20% in that range, that's a very good vitality metric, then you were closer to 30% within new products that are out there.

    我認為在第四季,就新近推出產品的活力指標(vitality rate)而言,我們大約在 20% 後段、接近 30% 的高 20% 區間。我的衡量方式通常是:如果能在 20% 以上,那就是非常好的活力指標;而我們更接近 30%,反映新產品在市場上的占比。

  • I think there's quite a bit of demand as we talked about for certain products in outpatient centers, and there's still quite a bit of demand in updating, in some levels, an older fleet within the acute hospitals around the world. Helmut, do you want to add anything?

    我認為,正如我們討論過的,門診中心對某些產品的需求相當可觀;而且在全球的急性醫院中,針對較舊設備機隊在某些層面進行更新的需求也仍然很強。Helmut,你要補充什麼嗎?

  • Helmut Zodl - GE HealthCare Intl

    Helmut Zodl - GE HealthCare Intl

  • Yes. I would just add, I think as Pete said, so the innovation and the new products are happening really across the portfolio. I would call out it's happening both on the device, and I talked about a couple of those innovation in my remarks, but it's also happening on the digital side.

    是的。我只想補充一下,我認為正如Pete所說,創新與新產品其實正在整個產品組合中發生。我會特別指出,這不僅發生在設備端——我在發言中也提到幾項創新——同時也發生在數位端。

  • So a lot of AI and machine learning that happens on the device accordingly, which is really a different way of introducing an NPI, so there's a lot of time spent on that by the team, which really helps clinicians significantly both get more productive but also have better patient outcomes.

    因此,很多AI與機器學習會相應地在設備端運行,這其實是一種引入NPI的不同方式,所以團隊在這方面投入了大量時間;這確實能顯著幫助臨床人員,不僅提升生產力,也能帶來更好的病患結果。

  • Peter Arduini: Yes, and the last part, Anthony, is I think from a service standpoint, as we sell these more highly-sophisticated products into the install base, 12 months out, the probability of capturing that for a service contract because of the sophistication of the product and really the limited amount of other folks that can provide the type of services needed for one of these advanced products will then become more reoccurring revenue growth down the road.

    Peter Arduini:是的,Anthony,最後一點是,我認為從服務的角度來看,當我們把這些更高階、更精密的產品銷售到既有裝機基礎中,約12個月之後,因為產品的複雜度,以及能提供這類先進產品所需服務的其他供應者相當有限,因此我們取得服務合約的機率會提高,進而在未來帶來更多經常性營收成長。

  • And so, that type of capture rate involved with leading products, it's an important part of our equation on growth.

    因此,這種與領先產品相關的取得率,是我們成長方程式中很重要的一部分。

  • Anthony Petrone - Mizhuo

    Anthony Petrone - Mizhuo

  • Very helpful. And quickly on capital allocation. It's been dynamic out of the gate here. You did the tuck-in with IMACTIS. We also had the debt recapitalization with the spin. And of course, you're doing internal investments with contrast, expanded the plant last year. So maybe just high-level comments on capital allocation when we think of internal investment the debt service out of the gate here post spin, tuck-in M&A and then return to free cash holders? Again, congratulations.

    非常有幫助。再快速問一下資本配置。你們一開始就很動態:做了與IMACTIS的補強型併購;也在分拆時進行了債務再資本化;當然,你們也在做內部投資,例如造影劑,去年擴建了工廠。所以,能否就資本配置給一些高層次的評論:當我們考量分拆後初期的內部投資、債務償付、補強型併購(tuck-in M&A),以及回饋自由現金流持有人時,你們的優先順序如何?再次恭喜。

  • Peter Arduini - GE HealthCare Intl

    Peter Arduini - GE HealthCare Intl

  • Yes. Thanks.

    是的,謝謝。

  • Helmut Zodl - GE HealthCare Intl

    Helmut Zodl - GE HealthCare Intl

  • Yes. Thanks, Anthony. So the way we look at our capital allocation, first and foremost, we are very happy with our strong investment-grade ratings we received last year. This is important for us access to capital, but it's also equally important for our customers. I mean, Pete just talked about long-term services contracts.

    是的,謝謝你,Anthony。我們看待資本配置的方式是:首先也是最重要的,我們對去年獲得的強勁投資級評等非常滿意。這對我們取得資金很重要,但對我們的客戶同樣重要。我的意思是,Pete剛才談到長期服務合約。

  • People want a strong financial partner that they know that's going to be with them for many years, sometimes decades only. So this is first and foremost, very important. Obviously, investing in the business is a key priority. We increased our R&D investment substantially in 2022.

    人們希望有一個財務實力強的合作夥伴,確信對方會在未來很多年、甚至有時是數十年都與他們同行。因此,這是首要且非常重要的。當然,投資業務是關鍵優先事項。我們在2022年大幅提高了研發投資。

  • It was up more than $1 billion that was spend on R&D now. And going forward, we expect that to really grow with the revenue. But when you then look at the rest of the capital allocation, obviously, this is a strong cash-generating business. I'm talking about 85% or more of free cash flow conversion.

    研發支出增加了超過10億美元。展望未來,我們預期研發投入將真正隨著營收成長而增加。但當你再看資本配置的其餘部分,顯然這是一個強勁的現金創造型業務。我指的是自由現金流轉換率達到85%或更高。

  • And we will use and deploy that cash to continue to invest organically into the business, but also out of the free cash flow, inorganic investment. IMACTIS was one example. Pete and I spent a lot of time with our M&A team to look at opportunities because I think it's important for us to see what is out there and make sure that we have good transparency and visibility and then make decisions that are going to be very disciplined for such acquisitions if they fit into our portfolio and they are accretive both at the topline growth but also from a profitability perspective.

    我們將運用並配置這些現金,持續進行對業務的有機投資,同時也會以自由現金流進行非有機投資。IMACTIS就是一個例子。Pete和我花了很多時間與我們的併購團隊一起評估機會,因為我認為了解市場上有哪些標的很重要,確保我們有良好的透明度與能見度,然後在這類收購若能融入我們的產品組合,並且在營收成長與獲利能力兩方面都具增益(accretive)時,做出非常嚴謹自律的決策。

  • Operator

    Operator

  • Our next question comes from Ryan Zimmerman with BTIG. Your line is open.

    我們的下一個問題來自BTIG的Ryan Zimmerman。您的線路已開通。

  • Ryan Zimmerman - BTIG

    Ryan Zimmerman - BTIG

  • Hey, thanks for taking the questions, and I echo everyone else's sentiments for the first quarter here. So just wanted to ask about two metrics that you're giving to The Street, and one is the book-to-bill ratio. I know there's been a lot of questions on it, but I would appreciate historical context in terms of how to think about that 1.07 ratio and how to think about it on a go-forward basis?

    嗨,謝謝讓我提問,我也呼應大家對第一季的看法。想請教你們提供給市場的兩個指標,其中之一是接單出貨比(book-to-bill)。我知道大家問了很多,但我希望能有一些歷史脈絡,幫助我們理解1.07這個比率,以及未來該如何看待?

  • If you could give us any quantitative perspective from prior quarters on the book-to-bill ratio and just how to think about that? And similarly in that vein, and I'll ask my follow-up, is is there's about $10 billion in remaining performance obligations, at least as of the filings?

    如果你們能提供前幾季接單出貨比的任何量化觀點,以及該如何解讀,將非常有幫助。同樣延伸這個問題,我也想追問:根據申報文件,截至目前大約有100億美元的剩餘履約義務(remaining performance obligations)。

  • And so, just if you can, Helmut, elaborate on the length of those obligations, how far those extend out, how those are realized over the coming quarters, and then how to think about that $10 billion on a go-forward basis? Is that kind of the par level to think about 4G healthcare as we think about it going forward? And if you'll be giving out these kind of metrics going forward? Thank you.

    所以,如果可以的話,Helmut,請你說明這些義務的期限有多長、延伸到多遠、在接下來幾季如何實現,以及未來該如何看待這100億美元?就我們往前看GE Healthcare時,這是否可視為一個大致的常態水準?以及你們是否會在未來持續提供這類指標?謝謝。

  • Helmut Zodl - GE HealthCare Intl

    Helmut Zodl - GE HealthCare Intl

  • Yes. So Ryan, I think to the RPO, we feel good about the Q4 in a book-to-bill ratio of 1.07. And this really, I think, demonstrated that the markets are strong. The book-to-bill, the way how we define it is really, I think, a quite simple calculation across the whole portfolio. And you must not forget we had quite a large services business in this as well where book-to-bill is one, also the PDX business for us has a book-to-bill of one.

    是的。Ryan,關於RPO,我們對Q4的接單出貨比1.07感到滿意。我認為這確實顯示市場很強勁。我們對接單出貨比的定義,其實是跨整個產品組合的一個相當簡單的計算。而你也不能忘記,我們其中包含相當大的服務業務,在那裡接單出貨比是1;另外我們的PDX業務接單出貨比也為1。

  • So when we look at [closed] portfolio, you will book-to-bill is actually higher in our imaging products where we have obviously from taking the order, ample shipment takes a longer time. And we are quite comfortable with the backlog.

    因此,當我們看([closed])產品組合時,你會看到在我們的影像產品中接單出貨比其實更高,因為從接單到出貨通常需要更長時間。我們對積壓訂單(backlog)相當有信心。

  • Historically that book-to-bill, I would say, has been running in similar ranges. It would have been up -- above the 1.10 level at certain quarters, if we look at historically. But it's running at the -- at the very solid bases at this stage.

    從歷史來看,我會說接單出貨比大致落在相近區間。若回顧歷史,在某些季度它曾高於1.10。但在目前階段,它仍維持在非常穩健的基礎上。

  • As it relates to our RPO, the RPO, as you mentioned, is a big amount that we have this close. And we are quite happy with the backlog. The RPO, the way it's defined, I want to be also maybe clear on it, defined as back of it is [non-cancelable]. So we also have backlog that is not -- that is [cancelable] where we see very, very little -- very few cancellations from our customers because they're committed to the products.

    至於RPO,如你所提到的,這是一個很大的金額,我們對這個積壓狀況感到相當滿意。我也想把RPO的定義說清楚:它被定義為([non-cancelable])的積壓訂單。因此我們也有一些不是——也就是([cancelable])的積壓訂單;但我們看到客戶取消的情況非常非常少,因為他們對產品是承諾的。

  • That's really how we look at RPO and we're exiting the year at a very strong position both on the RPO side as well as the total backlog. And just to be clear, the RPO, it is $14 billion. I don't know (inaudible) $10 billion number you quoted came from but it is $14 billion at the end of 2022.

    這就是我們看待RPO的方式;我們在年底時,無論是RPO或總積壓訂單都處於非常強勁的位置。再澄清一下,RPO是140億美元。我不確定你引用的100億美元數字是從哪裡來的,但截至2022年底是140億美元。

  • Ryan Zimmerman - BTIG

    Ryan Zimmerman - BTIG

  • Thanks, Helmut. Thanks for taking the questions.

    謝謝你,Helmut。謝謝讓我提問。

  • Helmut Zodl - GE HealthCare Intl

    Helmut Zodl - GE HealthCare Intl

  • Thank you.

    謝謝。

  • Peter Arduini - GE HealthCare Intl

    Peter Arduini - GE HealthCare Intl

  • Thanks, Ryan.

    謝謝你,Ryan。

  • Operator

    Operator

  • Thank you. Our next question from Jason Bednar with Piper Sandler. Your line is open.

    謝謝。我們的下一個問題來自Piper Sandler的Jason Bednar。您的線路已開通。

  • Jason Bednar - Piper Sandler

    Jason Bednar - Piper Sandler

  • Hey. Good morning everybody. And again, I'll echo the congratulations here on the quarter and the guide and with the spin and everything. I do want to touch here on China and build on the discussions from prior questions. I think most acknowledge there's some level of kind of demand in that market.

    嗨,大家早安。我也再次恭喜你們本季表現與指引,以及分拆等一切進展。我想談一下中國,並延續先前問題的討論。我想多數人都承認那個市場存在某種程度的需求。

  • I know you've referenced it, Pete. It might be tough to call right not but how do you see the China market unfolding here for GE Healthcare in 2023? And really as we look throughout the year if there's any cadence you'd like us to think about it. And then maybe if you could speak to what you've embedded in the guide for China this year?

    我知道你提過,Pete。現在可能還很難判斷,但你如何看GE Healthcare在2023年中國市場的發展?以及如果我們看全年,有沒有你希望我們留意的節奏?另外,你們今年的指引中對中國納入了哪些假設?

  • Peter Arduini - GE HealthCare Intl

    Peter Arduini - GE HealthCare Intl

  • Yes, Jason. I think -- look, I think, you know, China, it's obviously tricky to fully estimate how things will -- will play out. I mean we're cautiously optimistic. But again, if you pull the lens back, you look at the market. You take a look at how, in many cases procedures have been suppressed over the last 18 months at least, potentially even 24 months.

    是的,Jason。我認為——你看,中國顯然很難完全估計事情會——會如何發展。我們是審慎樂觀。不過,如果把視角拉遠、看整體市場,你會看到在許多情況下,過去至少18個月、甚至可能24個月,許多醫療處置量一直受到壓抑。

  • Things are clearly opening up and yes, there's challenges within the hospitals now with -- with COVID patients and such. But if we think of our own facilities that we've been able to keep running through Q4 when COVID levels were up 60, 70% in the environment, we were able to do that with learnings we had from how to run it in the first half of 2022.

    情況顯然正在開放;是的,醫院目前也面臨一些挑戰,例如COVID病患等。但如果我們看自己的工廠,在Q4當環境中的COVID水準上升60%、70%時,我們仍能維持運作;這得益於我們在2022年上半年學到的如何運營的經驗。

  • But we're now seeing a lot of those rates, particularly in the bigger cities where a lot of the businesses transacted to drop off quite a bit. And so our estimates would be Q1 I think is going to be a little bit choppy based on the type of products. If I think of flowable products like our PDX is tied to procedures, probably a lower level of a procedure volume in that quarter versus how we would see quarters two, three, and four.

    但我們現在看到許多這些比率,特別是在較大的城市,因為許多企業的交易量下滑得相當明顯。因此我們的估計是,第一季我認為會因產品類型而有些起伏。如果我想到像我們的 PDX 這類可消耗/可流動的產品,它與醫療處置量綁定,該季度的處置量水準可能會較低,相較於我們對第二、第三與第四季的看法。

  • But on equipment we actually would expect that it's still going to be reasonably strong and it's driven by a different dynamic, which is the stimulus funds that are out there and requiring products to be taken on install. We also make some products that help assist with COVID patients, whether it be monitoring events or other products and CT and stuff.

    但在設備方面,我們其實預期仍會相當強勁,而且是由不同的動能所驅動,也就是現有的刺激資金,並要求產品必須被採購並完成安裝。我們也有一些產品可協助 COVID 病患,不論是監測事件或其他產品,以及 CT 等相關產品。

  • So there's a bunch of different activities going on but we would expect that China will continue to ramp throughout the year. And again, we can't predict all the different changes that may take out but our take at this point in time is Q1 is a little bit more tempered and then continue improvement throughout the year.

    所以目前有一連串不同的活動在進行,但我們預期中國將在全年持續加速成長。同樣地,我們無法預測所有可能發生的變化,但就目前此刻我們的看法是,第一季會稍微保守一些,之後全年將持續改善。

  • Jason Bednar - Piper Sandler

    Jason Bednar - Piper Sandler

  • Okay. That's helpful. Thanks, Pete. And then maybe just as a follow-up with respect to pricing, I'll come back to that topic here. Pete, you and the team do have a lot of confidence in pricing [tailwind] supporting growth here going forward.

    好的。這很有幫助。謝謝你,Pete。接著也許作為關於定價的追問,我再回到這個主題。Pete,你和團隊對於定價這股[順風]在未來支持成長,確實很有信心。

  • I know we've talked a lot about price increases on products and goods. But I guess how are you seeing pricing play out in the services side of your business and are you anticipating similar pricing power there over time with your service contracts. Thank you.

    我知道我們談了很多產品與商品的漲價。但我想問的是,在你們業務的服務端,你們看到定價會如何發展?以及你們是否預期隨著時間推移,在服務合約上也會有類似的定價能力?謝謝。

  • Peter Arduini - GE HealthCare Intl

    Peter Arduini - GE HealthCare Intl

  • Yes, no. I think look, I would just say on broader pricing our job to get price really comes down to bring more value to the customer to help solve their problems. And the more we can create products that really solve a bigger issue, we can get our fair share of more pricing.

    是的。我的看法是,就更廣泛的定價而言,我們能夠取得價格的工作,歸根結底在於為客戶帶來更多價值、協助解決他們的問題。我們越能打造真正解決更大痛點的產品,就越能取得合理份額的更高定價。

  • And so having your organization, your teams aligned and thinking that way, having a gross margin focuses well is something we've just driven across the company and built in to compensation plans, built into focus. So I think -- I think that's a important part. And it goes for both equipment and services.

    因此,讓組織與團隊對齊並以這種方式思考、同時把毛利率作為重點,是我們在全公司推動的方向,也已納入薪酬計畫與工作重點之中。所以我認為——我認為這是很重要的一環,且同樣適用於設備與服務。

  • Obviously with services there's a different type of horizon using multi-year, how you think about it. We're also investing in innovative new services, whether they be different types of remote capabilities.

    顯然在服務方面,因為是多年期合約,思考的時間跨度不同。我們也正在投資創新的新服務,例如不同類型的遠端能力。

  • Again, when you think about the break fix side of our business, these are highly valuable products that being down for half a day or a day can wipe out a lot of profits for the institution. So if you have capabilities to be able to keep the product up and running, customers are able to pay more for that.

    再者,當你想到我們業務中的故障維修(break-fix)部分,這些都是高度有價值的產品,停機半天或一天就可能讓機構損失大量利潤。因此如果你具備讓產品維持運作的能力,客戶就願意為此支付更高費用。

  • The other aspect is there other services with an S on the end and some of those are digital on how you run your operation or how you can run capabilities. And in that -- those cases we can obviously ask for even higher prices as well as better margins than -- than what we would have for normal break fix.

    另一個面向是其他「服務」(services,複數)的內容,其中有些是數位化的,關於你如何營運你的作業或如何運行能力。在——在那些情況下,我們顯然可以要求更高的價格,同時也能取得比——比一般故障維修更好的毛利率。

  • But we've been successful at taking selective increases. And again, with more of these advanced products they related service contracts for them will also have a tale of better pricing down the road as well.

    但我們在選擇性調價方面一直很成功。同樣地,隨著這些更先進的產品推出,與其相關的服務合約在未來也會有更好的定價尾端效益。

  • Operator

    Operator

  • Our next question and our last question comes from Yuan Zhi with B. Riley. Your line is open.

    我們的下一個問題,也是最後一個問題,來自 B. Riley 的 Yuan Zhi。您的線路已開通。

  • Yuan Zhi - B. Riley Securities

    Yuan Zhi - B. Riley Securities

  • Good morning. This is Yuan. Thank you for taking our questions. I have a couple related to the pharmaceutical diagnose tech business. First, PDX. PDX was listed as a revenue priority. Can you elaborate on between molecular imaging and contrast media? Which segment will drive the gross you guys have imagined? And then I have a follow-up question, thank you.

    早安。我是 Yuan。謝謝你們回答我們的問題。我有幾個與藥品診斷技術業務相關的問題。第一個是 PDX。PDX 被列為營收優先項目。你能否進一步說明在分子影像與對比劑之間,哪一個分部會帶動你們所設想的毛利成長?我還有一個追問,謝謝。

  • Peter Arduini - GE HealthCare Intl

    Peter Arduini - GE HealthCare Intl

  • Yes. No, look, good question. PDX is definitely a growth driver. And again, I just want to reframe as we've talked about our businesses, all of them have growth opportunities and all of them have margin expansion but PDX has more of a growth priority up front.

    是的。這是個好問題。PDX 的確是成長驅動力。同樣地,我想重新框定一下:我們談到各項業務時,每一項都有成長機會,也都有毛利擴張空間,但 PDX 在前端更偏向成長優先。

  • And I think at both sides of the -- of the PDX, both are contrast business as well as our MI business we're expecting to see accelerated growth. As an example, in contrast with the growth of the imagining procedures that we're talking about, anything that needs a contrasted base capability like a vascular study, with our leadership position in contrast ionized imagining, we're going to continue to see that -- that increase.

    我認為在 PDX 的兩端——不論是對比劑業務或我們的分子影像(MI)業務——我們都預期會看到加速成長。舉例來說,在對比劑方面,隨著我們所談到的影像檢查處置量成長,任何需要對比增強能力的項目,例如血管研究,憑藉我們在離子型對比影像領域的領導地位,我們將持續看到那——那樣的增長。

  • So I think that's one. On the molecular imaging side, again, with the rise of new agents that are out there, whether they be in prostate or different neuroscience based agent, we would be expecting to see that pick up.

    所以我認為這是一點。在分子影像方面,同樣地,隨著市面上新藥劑的興起,不論是前列腺相關或不同的神經科學相關藥劑,我們預期會看到需求回升。

  • I would say the contrast agent is probably more of a temporal or closer '23 impact and the MI is probably -- has more or an impact later in '23 into '24 just to kind of give you a profile of how we think about the growth there.

    我會說對比劑可能是較具時點性、或更接近 2023 年的影響;而 MI 可能——在 2023 年後段到 2024 年會有更大的影響,這大致是我們對那邊成長輪廓的看法。

  • Yuan Zhi - B. Riley Securities

    Yuan Zhi - B. Riley Securities

  • Got it. Thank you for the helpful color there. The follow-up question is our understanding is that the product such as the [ultrasound] for ultrasound and Vizamyl for Alzheimer's disease [pass scan], maintaining a healthy growth margin. Can you maybe help us understand what prevents competitors to lower price and gain a larger market share while at the same time what stops other companies entering the space and making generic compounds of this product? Thank you.

    了解。謝謝你提供很有幫助的補充說明。追問是:我們的理解是,像是[超音波]用的產品,以及用於阿茲海默症[PET 掃描]的 Vizamyl,維持了健康的成長毛利。你能否幫我們理解,是什麼因素阻止競爭對手降價以取得更大市占?同時,又是什麼阻止其他公司進入這個領域,為這些產品製造學名(generic)化合物?謝謝。

  • Peter Arduini - GE HealthCare Intl

    Peter Arduini - GE HealthCare Intl

  • Yes. No, it's a good question. I would say, first of all, they do have healthy margins. One of the interesting things about our pharmaceutical diagnostic business both in contrast and MI that you had referenced is the proprietary nature of how we make it.

    是的。這是個好問題。我會先說,它們確實有健康的毛利。關於你提到的我們藥品診斷業務(包含對比劑與 MI),其中一個有趣之處在於我們製造方式的專有性。

  • I would say the capital hurdles of the infrastructure and then the sophistication of the infrastructure. And just to give an example, if there is a typical molecule in the pharmaceutical world that comes in a 10 mil vial and a generic comes out, people can have five ready, they can be shelf stable, they can be shipped around the world, stored for two years.

    我會說,進入門檻在於資本投入的基礎設施,以及該基礎設施的複雜度。舉例來說,如果在傳統藥品領域有一個典型分子以 10 毫升小瓶形式販售,當學名藥推出時,人們可以一次備好五瓶,它們可常溫穩定保存,可以運送到世界各地,並可儲存兩年。

  • Many of our agents are made that have half lifes, they're radioactive right, that only can live for maybe a couple days. And so you literally have to have production capabilities, cyclotron setup, a distribution network on how to delivery radioactive capabilities to pharmacies, we have that infrastructure and that know how.

    我們許多藥劑具有半衰期,它們是放射性的,可能只能存活幾天。因此你必須具備生產能力、迴旋加速器(cyclotron)配置,以及將放射性產品配送到藥局的物流配送網路;我們擁有那套基礎設施與專業 know-how。

  • And so even though some of these will have patents on them, the actual barriers to entry are more around the infrastructure and capability than they are based on particular IP and the normal pharmaceutical space.

    因此,即使其中一些產品有專利,實際的進入障礙更多在於基礎設施與能力,而不是特定的智慧財產(IP),也不同於一般的傳統製藥領域。

  • Operator

    Operator

  • That concludes the question and answer session. Please proceed with any closing remarks.

    問答環節到此結束。請進行任何結語。

  • Peter Arduini - GE HealthCare Intl

    Peter Arduini - GE HealthCare Intl

  • Thank you. So look, in closing, let me just reiterate how excited I am about our path forward as we invest in our business. The emphasis on innovative products in high growth areas, many we talked about today. We delivered strong organic revenue growth and sequential margin improvement fourth quarter and we expect to capitalize on robust demand in '23 as we execute on our revenue drivers across each of our segments.

    謝謝。最後,讓我再次強調,當我們投資於業務時,我對我們未來的道路感到非常振奮。我們強調在高成長領域推出創新產品,今天也談到了許多。我們在第四季實現了強勁的有機營收成長與連續性的毛利率改善,並預期在 2023 年執行各事業部的營收驅動因素之際,把握強勁需求。

  • And we're also optimizing the business through lean. We've given quite a few examples today and this gives us confidence in our ability to reach our margin targets and drive meaningful shareholder value over the long term.

    我們也透過精實(lean)來優化業務。今天我們提供了不少例子,這讓我們對達成毛利率目標、並在長期推動具意義的股東價值更有信心。

  • Our full team is united and excited about our purpose driven approach for the benefit of customers and most importantly patients that we serve. So thank you for joining us today and we look forward to seeing you at one of our upcoming conferences that we'll attend. Thank you very much.

    我們整個團隊團結一致,並對以使命驅動的方法、造福客戶,最重要的是我們所服務的病患,感到振奮。謝謝各位今天加入我們,也期待在我們接下來將參與的會議之一與各位見面。非常感謝。

  • Operator

    Operator

  • Thank you, ladies and gentlemen. This concludes today's conference. Thank you for participating, you may now disconnect. Everyone, have a great day.

    謝謝各位女士先生。今天的電話會議到此結束。感謝各位參與,您現在可以掛線。祝各位有美好的一天。